December 2016 Briefing – Hematology & Oncology
Here are what the editors at HealthDay consider to be the most important developments in Hematology & Oncology for December 2016. This roundup includes...
No Effect for BUP TAP Catheter on Chronic Pain After Breast Recon
No difference in chronic postsurgical pain incidence for TAP catheter delivering bupivacaine, saline
BodyFIX Without Wrap Works for Radiotherapy Immobilization
Compared to two other immobilization devices, BodyFIX was preferred by staff
Uric Acid May Mark Progression for Nasopharyngeal Cancer
High pretreatment uric acid may be clinical biomarker for lung metastasis
Panel of 88 SNPs Predicts Breast CA Risk in Women at High Risk
SNP88 is independent of Tyrer-Cuzick model; improved prediction when combined multiplicatively
Triple-Negative Breast CA Risk Up for Blacks With Benign Breast Dz
Increased risk of TNBC among African-American women with prior diagnosis of benign breast disease
Reoperation Risk for Nonpalpable Breast Lesions Higher for DCIS
Reoperation rate low after wire-guided breast conserving sx, but higher for DCIS than invasive BC
Selumetinib Active in Children With Neurofibromatosis Type 1
Patients were able to receive selumetinib on long-term basis; maximum tolerated dose 25 mg/m²
Case Report: Adoptive T-Cell Tx Shows Promise in Glioblastoma
Tumors regressed after intracranial infusions of T cells engineered to target tumor-associated antigen
Iron Deficiency Anemia Ups Risk of Hearing Loss in U.S. Adults
After adjustment for sex, adults with IDA have increased odds of SNHL, combined hearing loss
